Pfizer has abandoned the development of a small-molecule oral GLP-1 agonist.
Pfizer has decided to discontinue development of danugliprone, a small-molecule glucagon-like peptide-1 receptor agonist for oral administration, according to a company press release. The decision was prompted by serious side effects…
